ASH 2022 Conference Coverage
ASH 2022 Phase III SUNMO Trial: Evaluating the Efficacy & Safety of Mosunetuzumab + Polatuzumab Vedotin vs. Rituximab + Gemcitabine & Oxaliplatin in R/R Aggressive B-Cell NHL
By
ASH 2022 Conference Coverage
FEATURING
Jason Westin
By
ASH 2022 Conference Coverage
FEATURING
Jason Westin
Login to view comments.
Click here to Login